Raymond James Financial
COGT icon

Raymond James Financial’s Cogent Biosciences COGT Stock Holding History

Raymond James Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Buy
673,676
+303,961
+82% +$10.6M 0.01% 1370
2026
Q1 		$14.2M Sell
369,715
-6,204
-2% -$229K ﹤0.01% 1732
2025
Q4 		$13.4M Buy
375,919
+86,522
+30% +$2.43M ﹤0.01% 1740
2025
Q3 		$4.16M Buy
289,397
+289,352
+643,004% +$3.43M ﹤0.01% 2595
2025
Q2 		$323 Buy
+45
New +$249 ﹤0.01% 6731

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raymond James Financial's COGT Position: Q2 2026 in Review

Raymond James Financial increased its Cogent Biosciences (COGT) stake by 82% in Q2 2026, buying an estimated $10.6M and bringing the position to 673,676 shares worth $26.1M. The position accounts for 0.01% of the portfolio, ranked #1370.

Raymond James Financial first reported a position in COGT in Q2 2025 and has held it in 5 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Raymond James Financial held 673,676 shares of Cogent Biosciences worth $26.1M as of Q2 2026.
  • Raymond James Financial bought 303,961 Cogent Biosciences shares in Q2 2026, an estimated $10.6M.
  • Cogent Biosciences made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1370 holding.
  • Raymond James Financial first reported a position in Cogent Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.